{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:29:58Z","timestamp":1791912598839,"version":"4.3.4"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Ketamin und Esketamin k\u00f6nnen bei therapieresistenter Depression oder in\n                    psychiatrischen Notfallsituationen rasch antidepressive Effekte entfalten. Die\n                    Ketamin-augmentierte Psychotherapie (KAP) nutzt diese Wirkung gezielt: Die\n                    Substanzen werden mit Psychotherapiesitzungen kombiniert, um \u00fcber eine\n                    vor\u00fcbergehend erh\u00f6hte synaptische Plastizit\u00e4t ein \u201etherapeutisches Fenster\u201c zu\n                    er\u00f6ffnen und psychotherapeutische Prozesse zu vertiefen.<\/jats:p>","DOI":"10.1055\/a-2742-4611","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:46:21Z","timestamp":1778712381000},"page":"193-207","source":"Crossref","is-referenced-by-count":1,"title":["Ketamin und Esketamin bei der therapieresistenten\n                    Depression"],"prefix":"10.1055","volume":"94","author":[{"given":"Cornelius","family":"Sch\u00fcle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sobieraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Rogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41386-021-01122-2","article-title":"Novel approaches to estimate prefrontal synaptic strength in vivo in humans: of\n                    relevance to depression, schizophrenia, and ketamine","volume":"47","author":"C G Abdallah","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New\n                    Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized,\n                    Double-Blind, Active-Controlled Study (TRANSFORM-1)","volume":"22","author":"M Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jcph.122","article-title":"Repeated S-ketamine infusions in therapy resistant depression: a case\n                    series","volume":"53","author":"F Segmiller","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant\n                    Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial","volume":"75","author":"E J Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a\n                    Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A\n                    Randomized Double-Blind Active-Controlled Study","volume":"176","author":"V Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in\n                    Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3","volume":"28","author":"R Ochs-Ross","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for\n                    Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized\n                    Clinical Trial","volume":"76","author":"E J Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"19m1319","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine Nasal Spray for Rapid Reduction of Major Depressive\n                    Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent:\n                    Double-Blind, Randomized Study (ASPIRE I)","volume":"81","author":"D J Fu","year":"2020","journal-title":"J Clin\n                    Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients\n                    With Major Depressive Disorder Who Have Active Suicide Ideation With Intent:\n                    Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)","volume":"24","author":"D F Ionescu","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"112629","DOI":"10.1016\/j.bbr.2020.112629","article-title":"Ketamine as a mental health treatment: Are acute psychoactive effects associated\n                    with outcomes? A systematic review","volume":"392","author":"M Grabski","year":"2020","journal-title":"Behav Brain Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ijnp\/pyab084","article-title":"Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal\n                    Spray in Patients With Treatment-Resistant Depression","volume":"25","author":"G Chen","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00213-023-06324-8","article-title":"Reconsidering \"dissociation\" as a predictor of antidepressant efficacy\n                    for esketamine","volume":"240","author":"D S Mathai","year":"2023","journal-title":"Psychopharmacology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e20220593","DOI":"10.47626\/2237-6089-2022-0593","article-title":"Does the intensity of dissociation predict antidepressant\n                    effects 24 hours after infusion of racemic ketamine or esketamine in\n                    treatment-resistant depression? A secondary analysis from a randomized\n                    controlled trial","volume":"47","author":"MV F Echegaray","year":"2025","journal-title":"Trends Psychiatry Psychother"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and Psychedelic-Assisted Psychotherapy","volume":"177","author":"C M Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41386-019-0317-8","article-title":"Impact of midazolam vs. saline on effect size estimates in controlled trials of\n                    ketamine as a rapid-acting antidepressant","volume":"44","author":"S T Wilkinson","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a\n                    two-site randomized controlled trial","volume":"170","author":"J W Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamapsychiatry.2025.3019","article-title":"Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for\n                    Depression: The KARMA-Dep 2 Randomized Clinical Trial","volume":"82","author":"A Jelovac","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e2524119","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control Group Outcomes in Trials of Psilocybin, SSRIs, or\n                    Esketamine for Depression: A Meta-Analysis","volume":"8","author":"F Hieronymus","year":"2025","journal-title":"JAMA Netw\n                    Open"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1055\/a-2261-0745","article-title":"Neurobiologie und Wirkmodelle zu Psychedelika","volume":"43","author":"U Herwig","year":"2024","journal-title":"Nervenheilkunde"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral\n                    Modification to Treat Cocaine Dependence: A Randomized Clinical Trial","volume":"176","author":"E Dakwar","year":"2019","journal-title":"Am J Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for\n                    Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial","volume":"177","author":"E Dakwar","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: immediate effects and two-year\n                    follow-up","volume":"23","author":"E Krupitsky","year":"2002","journal-title":"J Subst Abuse Treat"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000517074","article-title":"Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine\n                    in Treatment-Resistant Depression: A Randomized Clinical Trial","volume":"90","author":"S T Wilkinson","year":"2021","journal-title":"Psychother Psychosom"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1176\/appi.ajp.20220216","article-title":"A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect\n                    of a Single Ketamine Infusion: A Randomized Clinical Trial","volume":"179","author":"R B Price","year":"2022","journal-title":"Am J Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.bbapap.2018.03.006","article-title":"d-Serine is a potential biomarker for clinical response in treatment of\n                    post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER\n                    psychotherapy: A pilot study","volume":"1866","author":"B Pradhan","year":"2018","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"20l13406","DOI":"10.4088\/JCP.20l13406","article-title":"A Proof-of-Concept Study of Subanesthetic Intravenous Ketamine\n                    Combined With Prolonged Exposure Therapy Among Veterans With Posttraumatic\n                    Stress Disorder","volume":"81","author":"P R Shiroma","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000507095","article-title":"Continuous Ketamine Infusion for Pain as an Opportunity for Psychotherapy for\n                    PTSD: A Case Series of Ketamine-Enhanced Psychotherapy for PTSD and Pain\n                    (KEP-P2)","volume":"89","author":"B M Keizer","year":"2020","journal-title":"Psychother Psychosom"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2742-4611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:46:35Z","timestamp":1778712395000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2742-4611"}},"subtitle":["Pharmakologische Effekte und augmentierte Psychotherapie"],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2742-4611","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}